Bone Biologics Corporation
BBLG
$0.6899
$0.02393.59%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.60% | 13.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 63.50% | 17.45% | |||
| Operating Income | -63.50% | -17.45% | |||
| Income Before Tax | -61.71% | -20.07% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -61.71% | -20.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -61.71% | -20.07% | |||
| EBIT | -63.50% | -17.45% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 74.10% | -253.13% | |||
| Normalized Basic EPS | -14.34% | 19.99% | |||
| EPS Diluted | 74.10% | -253.13% | |||
| Normalized Diluted EPS | -14.34% | 19.99% | |||
| Average Basic Shares Outstanding | 41.45% | 50.07% | |||
| Average Diluted Shares Outstanding | 41.45% | 50.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||